Merck, 94101450-1VL, AT-2.1

Biochem/physiol Actions
AT-2.1 was developed via in vivo passages of the Dunning R-3327 rat prostatic cancers. A series of other cell lines were produced and they hold in common with Dunning R-3327 and AT-2.1 a structural change in chromosome 4 involving a translocation.
Rat prostatic cancer
Preparation Note
RPMI 1640 + 2mM Glutamine + 250nM Dexamethasone (DXMT) + 10% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) 1:3 to 1:10 i.e. seeding at 1-4x10,000 cells/ml. Cells can be easily dislodged from the monolayer mechanically, however 0.25% trypsin or trypsin/EDTA can be used; 5% CO₂; 37°C.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].